Third, although we and another group previously identified downregulation of CPT2 as a critical factor for acylcarnitine accumulation in HCC tissues10,22, the mechanism underlying the changes in serum acylcarnitine profiles during the progression of NAFLD remains unclear. This evidence concerns the gene CPT2 and hepatocellular carcinoma.